Dorzagliatin: First Approval
- 30 November 2022
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 82 (18) , 1745-1750
Abstract
Dorzagliatin (HuaTangNing) is an oral glucokinase activator that is being developed by Hua Medicine for the treatment of type 2 diabetes mellitus (T2DM), type 1 diabetes mellitus (T1DM) and diabetic kidney disease (DKD). Dorzagliatin improves glycaemic control by activating pancreatic and hepatic glucokinase in a glucose-dependent manner. In September 2022, dorzagliatin (with diet control and exercise) as monotherapy and as an add-on to metformin (when glycaemic control is inadequate with metformin alone) was approved in China for improving glycaemic control in adult patients with T2DM. This article summarizes the milestones in the development of dorzagliatin leading to this first approval.Keywords
This publication has 14 references indexed in Scilit:
- Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialNature Medicine, 2022
- Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonistsJournal of Enzyme Inhibition and Medicinal Chemistry, 2022
- Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activatorClinical and Translational Science, 2021
- 117-LB: Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP-1 Release in T2D Patients and Is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta-Cell FunctionDiabetes, 2021
- Glucokinase Activators for Type 2 Diabetes: Challenges and Future DevelopmentsDrugs, 2020
- The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of LangerhansFrontiers in Physiology, 2019
- Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 studyThe Lancet Diabetes & Endocrinology, 2018
- Dorzagliatin (HMS5552), a novel dual‐acting glucokinase activator, improves glycaemic control and pancreatic β‐cell function in patients with type 2 diabetes: A 28‐day treatment study using biomarker‐guided patient selectionDiabetes, Obesity and Metabolism, 2018
- Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm ProcessClinical Pharmacokinetics, 2016
- Glucokinase activators (GKAs) promise a new pharmacotherapy for diabeticsF1000 Medicine Reports, 2010